Parexel expands in the U.K. after an eClinical buyout

Parexel International ($PRXL) is widening its presence in Nottingham, U.K., tapping local grant funds to consolidate some outposts with plans to grow around its latest acquisition.

With the help of two grants totaling nearly £1 million ($1.6 million), Parexel plans to take over a 62,000-square-foot operation formerly occupied by BT, according to the Nottingham Post, relocating workers from nearby offices. The CRO first came to the area through its 2008 acquisition of ClinPhone, a randomization and trial supply management (RTSM) organization, and Parexel has about 600 employees already in Nottingham.

Now, after disclosing its acquisition of the U.K. RTSM provider ClinIntel earlier this month, Parexel plans to build around what it has in Nottingham, adding more jobs as it settles into its new location next year.

"Parexel's Nottingham operations play an important role in helping the company advance the worldwide success of the biopharmaceutical and medical device industries in preventing and curing disease," the company said in a statement.

The expansion is also an affirmation of the company's focus on RTSM, through which it offers software that allows sponsors and CROs to handle patient data, site information and inventory management. Parexel plans to merge ClinIntel's technology into its ClinPhone platform, which the company says can help its clients more quickly get off the ground at the study start-up stage, when sponsors must juggle screening, enrollment, drug dispensation and supply distribution all at once.

- read the story
- here's the announcement

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.